SLC1A2 and myeloid sarcoma: Wilcoxon Signed Rank test for paired samples showed a significant difference between EV-EAAT2 percentages in relapse and remission (p = 0.002), confirming the association of highest plasma EV-EAAT2 levels with MS relapses.